MYOMO, INC. - 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: MYOMO, INC. (NYSE American: MYO)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Myomo is a wearable medical robotics company developing the MyoPro, a myoelectric-controlled upper limb orthosis for patients with neuromuscular disorders (e.g., stroke, spinal cord injury). The company primarily operates via a "direct billing" model, providing devices to patients and billing insurance payers directly, though it also sells to Orthotics and Prosthetics (O&P) providers and the Veterans Administration (VA).
Key Milestone: In 2024, the Centers for Medicare and Medicaid Services (CMS) reclassified the MyoPro from durable medical equipment to a brace, enabling lump-sum reimbursement rather than rental, effective January 1, 2024.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $32.55 million | $19.24 million | +69% |
| Product Revenue | $32.55 million | $17.48 million | +86% |
| Gross Profit | $23.19 million | $13.18 million | +76% |
| Gross Margin | 71.2% | 68.5% | +2.7 pts |
| Net Loss | $(6.18) million | $(8.15) million | -24% (Improvement) |
| Operating Expenses | $29.39 million | $21.41 million | +37% |
| Cash & Equivalents (End of Period) | $24.37 million | $6.87 million | +255% |
| Working Capital | $22.62 million | $8.17 million | +177% |
Adjusted EBITDA: $(5.13) million for 2024 compared to $(6.95) million for 2023.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 33% increase in the reimbursement pipeline (1,389 patients) and an 18% increase in backlog (272 units). The shift to Medicare Part B lump-sum reimbursement significantly increased the average selling price (ASP) and unit volume.
- Cost Structure: Operating expenses rose 37% due to increased headcount in engineering (R&D +81%), clinical/reimbursement staff, and higher advertising spend to fuel the direct billing channel.
- Liquidity Position: Cash position improved dramatically from $6.9 million to $24.4 million, bolstered by a December 2024 public offering ($15.8 million net proceeds) and a January 2024 registered direct offering ($5.4 million net proceeds).
- License Revenue: License revenue dropped to zero in 2024 compared to $1.76 million in 2023, as the upfront fee from the China joint venture was fully recognized in the prior year.
Guidance, Outlook, and Risks
Outlook & Strategy:
- Management plans to invest heavily in 2025 to expand clinical, reimbursement, and manufacturing capacity to support the direct billing channel.
- Expectations include negative cash flows for the first three quarters of 2025 due to these growth investments.
- Goal is to achieve cash flow breakeven on a quarterly basis by the fourth quarter of 2025.
- Manufacturing capacity is currently 120 units/month, with plans to expand space in June 2025.
Key Risks & Contingencies:
- Reimbursement Concentration: 49% of total revenue came from Medicare Part B, and 25% from Medicare Advantage plans. Adverse changes in CMS policies or payer denials pose a significant risk.
- Internal Controls: The company identified a material weakness in internal controls over financial reporting related to IT general controls (privileged access rights, user provisioning, and change management). Remediation is planned for Q1 2025.
- Supply Chain: Reliance on a single third-party manufacturer (Cogmedix) for key subassemblies and limited suppliers for components.
- Capital Requirements: While current cash is sufficient for 12 months, continued losses and expansion plans may require additional capital raises.
Investor Verification Checklist
- Reimbursement Stability: Verify the sustainability of Medicare Part B lump-sum reimbursement rates and monitor for any CMS policy changes or increased audit activity.
- Internal Control Remediation: Confirm the successful remediation of the material weakness in IT general controls in the upcoming 10-Q filings.
- Cash Burn Rate: Monitor quarterly cash flow from operations to ensure the company can sustain its growth investments without immediate dilution or debt distress.
- Backlog Conversion: Track the conversion rate of the $13.6 million backlog into recognized revenue to validate growth projections.
- Supply Chain Resilience: Assess the company's contingency plans for its single-source manufacturing partner (Cogmedix).